前往化源商城

51-83-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL746418
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1999
Volume: 42
Issue: 11
First Page: 1999
Last Page: 2006
DOI: 10.1021/jm9910019

Target ChEMBL ID: CHEMBL216
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.071EC50=71nM
0.1109EC50=110.9nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL746423
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
12EC50=12000nM
6.9EC50=6900nM
5.7EC50=5700nM
5.4EC50=5400nM
14EC50=14000nM
41EC50=41000nM
560EC50=560000nMOutside typical range
80EC50=80000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL746421
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1999
Volume: 42
Issue: 11
First Page: 1999
Last Page: 2006
DOI: 10.1021/jm9910019

Target ChEMBL ID: CHEMBL216
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Max=99%
Max=65.6%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL745520
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2003
Volume: 46
Issue: 20
First Page: 4273
Last Page: 4286
DOI: 10.1021/jm0301235

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Activity=350%
Activity=280%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL746367
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 1998
Volume: 41
Issue: 14
First Page: 2524
Last Page: 2536
DOI: 10.1021/jm960683m

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
4568ED50=4568uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Rattus norvegicus
External ID: CHEMBL984889
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 9
First Page: 3084
Last Page: 3092
DOI: 10.1021/jm900025h

Target ChEMBL ID: CHEMBL376
ChEMBL Target Name: Rattus norvegicus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=55.8%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL746366
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2188
Last Page: 2195
DOI: 10.1021/jm00012a019

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.62EC50=620nM
0.5EC50=500nM
0.13EC50=130nM
0.14EC50=140nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL746514
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 26
First Page: 4265
Last Page: 4280
DOI: 10.1021/jm9702903

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.3IC50=300nM
5.4IC50=5400nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL746518
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2000
Volume: 43
Issue: 13
First Page: 2514
Last Page: 2522
DOI: 10.1021/jm9904001

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=4%
Inhibition=28%
Inhibition=28%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL3367782
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 15
First Page: 3255
Last Page: 3259
DOI: 10.1016/j.bmcl.2014.06.020

Target ChEMBL ID: CHEMBL216
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10.9648Ki=10964.78nM
30.1995Ki=30199.52nM
100Ki>100000nM
100Ki>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M2
External ID: CHEMBL3367783
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 15
First Page: 3255
Last Page: 3259
DOI: 10.1016/j.bmcl.2014.06.020

Target ChEMBL ID: CHEMBL211
ChEMBL Target Name: Muscarinic acetylcholine receptor M2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
1.20226Ki=1202.26nM
2.0893Ki=2089.3nM
100Ki>100000nM
100Ki>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M5
External ID: CHEMBL3367786
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 15
First Page: 3255
Last Page: 3259
DOI: 10.1016/j.bmcl.2014.06.020

Target ChEMBL ID: CHEMBL2035
ChEMBL Target Name: Muscarinic acetylcholine receptor M5
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
7.76247Ki=7762.47nM
100Ki>100000nM
100Ki>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL3367784
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 15
First Page: 3255
Last Page: 3259
DOI: 10.1016/j.bmcl.2014.06.020

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
13.4896Ki=13489.63nM
7.58578Ki=7585.78nM
100Ki>100000nM
100Ki>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M4
External ID: CHEMBL3367785
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 15
First Page: 3255
Last Page: 3259
DOI: 10.1016/j.bmcl.2014.06.020

Target ChEMBL ID: CHEMBL1821
ChEMBL Target Name: Muscarinic acetylcholine receptor M4
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
8.91251Ki=8912.51nM
11.4815Ki=11481.54nM
100Ki>100000nM
100Ki>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL845472
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1986
Volume: 29
Issue: 9
First Page: 1610
Last Page: 1615
DOI: 10.1021/jm00159a009
Standard TypeStandard RelationStandard Value
Ratio=1
Ratio=0.4
Ratio>124
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL845474
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 1
First Page: 164
Last Page: 168
DOI: 10.1021/jm00396a025
Standard TypeStandard RelationStandard Value
Ratio=1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M2
External ID: CHEMBL852858
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1990
Volume: 33
Issue: 4
First Page: 1128
Last Page: 1138
DOI: 10.1021/jm00166a008

Target ChEMBL ID: CHEMBL1907609
ChEMBL Target Name: Muscarinic acetylcholine receptor
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: H - Homologous protein target assigned
Confidence: Multiple homologous protein targets may be assigned
Standard TypeStandard RelationStandard Value
Ratio=4100
Ratio=560
Ratio=390
Ratio=1200
Ratio=490
Ratio=370
Ratio=130
Ratio=38
Ratio=4100
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748964
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=83.4%
Inhibition=99.4%
Inhibition=98.5%
Inhibition=68.5%
Inhibition=76.5%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748965
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=99.8%
Inhibition=101%
Inhibition=100%
Inhibition=97.9%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748962
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=16.5%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL682997
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 1
First Page: 164
Last Page: 168
DOI: 10.1021/jm00396a025
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
66.2EC50=66200nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Rattus norvegicus
External ID: CHEMBL774807
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 1992
Volume: 2
Issue: 8
First Page: 781
Last Page: 786
DOI: 10.1016/S0960-894X(00)80531-4

Target ChEMBL ID: CHEMBL376
ChEMBL Target Name: Rattus norvegicus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Activity=580
Activity=230
Activity=130
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748968
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.00231Ki=2.31nM
0.0174Ki=17.4nM
0.00901Ki=9.01nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL682999
Protocol: N/A
Comment: Journal: J Med Chem
Year: 1987
Volume: 30
Issue: 10
First Page: 1934
Last Page: 1938
DOI: 10.1021/jm00393a042
Standard TypeStandard RelationStandard Value
ED50=5.1
ED50>5
ED50=6.1
ED50=1.7
ED50=2.3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748967
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.014Ki=14nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL682859
Protocol: N/A
Comment: Journal: J Med Chem
Year: 1986
Volume: 29
Issue: 9
First Page: 1610
Last Page: 1615
DOI: 10.1021/jm00159a009
Standard TypeStandard RelationStandard Value
ED50=4.04E-6
ED50>5.0E-4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748052
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 8
First Page: 1230
Last Page: 1246
DOI: 10.1021/jm960467d

Target ChEMBL ID: CHEMBL3733
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Smax=630%
Smax=180%
Smax=120%
Smax=98%
Smax=180%
Smax=330%
Smax=400%
Smax=590%
Smax=660%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M1
External ID: CHEMBL748216
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1998
Volume: 41
Issue: 12
First Page: 2047
Last Page: 2055
DOI: 10.1021/jm9705115

Target ChEMBL ID: CHEMBL276
ChEMBL Target Name: Muscarinic acetylcholine receptor M1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.4EC50=400nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR541
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO, was added using a Flying Reagent Dispenser to generate a final concentration of 50 nM CITCO inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inhibitor3.349141.215910Single point of activity-5.47514.95490.5085-42.7363-1.5203-30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-8.087121.89-8.6781-3.6855-6.25695.4433-2.2253-6.5947-10.7583-4.5705-16.1608-16.3686-5.5938-8.0871QC'd by ACCInactive0
Inhibitor2.660331.350422Complete curve; partial efficacy-5.57514.95490.7593-35.7832-4.4328-1.20 0 0 0 0 0 0 0 0 0 0 0 0 1 1-7.07487.0287-3.7117-8.93987.0191-8.6003-10.5811-9.6323-3.5772-9.7824-21.4714-32.0269-13.6825-7.0748QC'd by ACCInactive0
Inhibitor29.8493180.333140Partial curve; high efficacy-4.52511.86170.9403-183.9808-3.6476-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-139.3794-6.9891-4.5485-2.48725.72942.1105-4.4422-5.01950.98326.5263-18.8291-30.3545-53.8001-139.3794QC'd by ACCInhibitor29.8493162.790140Partial curve; high efficacy-4.52513.24750.9553
Inactive0-4.77512.40640.4777-19.93010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.4418-5.3665-6.0776-0.6378-0.7746-5.95928.056814.4063-4.2029-2.83313.6942-1.1786-14.0414-17.4418QC'd by ACCInactive0-4.57513.1320.6731
Inactive0-4.04014.95490.487724-5.718340 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6907-9.6058-16.8485-11.179-0.45450.0756-9.022-7.6078-4.898-2.6992-0.66814.3314-11.422917.6907QC'd by RTIActivator64.553243.03530Partial curve; partial efficacy-4.19013.92950.9117
Inactive0004-19.84863.3433-23.4364-34.1329-6.2414-5.0556-25.546-8.9103-6.9329-28.1976-6.81633.8592-42.036-19.8486QC'd by RTIActivator67.057937.01130Partial curve; partial efficacy; poor fit-4.17353.67720.7941
Inactive0-4.02734.95490.655322-3.294740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.0345-2.80161.8842-7.0081-1.7985-7.3345-5.4629-6.0156-0.7765-1.4972-8.9956-1.9725-7.487516.0345QC'd by RTIInactive0-4.27732.33320.6095
Inactive00047.8644-12.2433-5.1181-4.04961.28844.3493-4.5231-6.8637-4.8147-7.4445-2.1022-11.7632-20.07367.8644QC'd by RTIInactive0-4.37991.96730.5769
Inactive000412.77776.2553-5.7998-3.9544-6.27073.8508-4.3153-0.2911-4.79463.74813.8044.64191.374312.7777QC'd by RTIInactive0-4.28464.95490.3638
Inactive0-4.20534.44950.6434-17.42521.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.7713.79853.86442.4904-4.2833.78225.42352.6092-2.38-3.39182.70615.627-2.5037-15.771QC'd by RTIInactive0-5.20534.95490.321
Inhibitor5.9059106.654984Complete curve; high efficacy-5.228710.9844-102.49964.1553-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.8049.49943.6503-0.42471.07452.82466.38180.0721-15.1461-24.7454-55.3584-79.6141-94.3827-85.804QC'd by RTIInhibitor4.691398.416784Complete curve; high efficacy-5.32870.90.9674
Inactive0-4.69341.55790.702223-4.449740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3595-2.1806-3.3591-6.2651-0.28090.121-6.0475-11.7066-7.89250.86856.2708-0.375526.069416.3595QC'd by RTIActivator71.880946.06290Single point of activity-4.14344.95490.7673
Inhibitor69.1718135.093943Partial curve; high efficacy-4.16013.06540.9789-149.2252-14.1313-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-117.8714-2.1311-17.2291-13.9078-13.6919-19.6465-13.3695-15.7919-17.4807-14.0473-10.7354-16.145-44.1916-117.8714QC'd by RTIInhibitor54.9451147.633342Partial curve; high efficacy-4.26012.40640.9628
Inactive0-6.14174.95490.4637-11.0778-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.73651.2389-2.2448-12.4683-0.62132.0757-1.40511.6174-8.0337-11.8106-11.9614-1.3448-17.9815-2.7365QC'd by RTIInactive0-4.34170.50.4602
Inhibitor8.844263.970182Complete curve; high efficacy-5.05331.46410.9355-69.4155-5.4454-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.4281-3.3461-7.3817-5.25411.5957-7.1494-6.1151-2.5632-12.7008-17.0044-40.829-49.2957-77.8583-59.4281QC'd by RTIInhibitor7.882431.683321Complete curve; partial efficacy-5.10332.33320.905
Inhibitor19.477457.938541Partial curve; partial efficacy-4.71051.34430.9334-57.56260.376-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0338-12.41210.71942.24359.20663.0773-1.07773.1429-3.055-5.8935-11.5387-32.2284-42.404-52.0338QC'd by RTIInhibitor77.540938.538210Single point of activity-4.11054.95490.5991
Inactive0004-3.3574-9.0659-5.0523-7.9611.8345-6.6475-6.4054-4.0807-7.994-5.2589-4.8636-18.8381-16.5327-3.3574QC'd by RTIInactive0-5.70264.95490.3553
Inactive0-4.09594.95490.659231.5-0.506240 0 0 0 0 0 0 0 0 0 0 0 0 0 025.14185.9174-1.2243-9.58850.3121-2.79136.44825.5515-1.4762-0.4167-3.92814.3971-4.45225.1418QC'd by RTIActivator56.764849.34910Partial curve; partial efficacy-4.24591.80790.7545
Inactive000411.60064.5643-3.7194-10.097311.42282.41525.31161.6689-4.6133-3.7747-3.13611.8656-13.87311.6006QC'd by RTIInactive0-4.14513.29750.4562
Inactive0-4.06414.95490.569122-3.35640 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3590.1187-1.3367-4.6228-5.1472-1.2162-0.1657-0.04880.0689-5.7723-5.23-1.7902-11.963316.359QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR611
Protocol: Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195, was added using a Flying Reagent Dispenser to generate a final concentration of 0.75 uM PK11195 inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.36620.69570.44051.11090.5787-0.2699-0.32331.18450.0326-1.0092-1.73120.8267-2.1104-2.3662QC'd by SigmaAldrichInactive0
Inactive0004-0.2849-0.47850.10371.13040.3494-1.2942-2.3851-1.60740.1233-0.8459-1.8941-2.6451-0.2138-0.2849QC'd by SigmaAldrichInactive0
Activator53.984430.302520Partial curve; partial efficacy-4.26772.04370.980730-0.30252.20 0 0 0 0 0 0 0 0 0 0 0 0 0 022.9705-0.53970.19140.0778-0.1425-0.2776-1.9188-0.46281.1362-0.8514-0.42823.186710.348822.9705QC'd by SigmaAldrichActivator27.056334.152540Partial curve; high efficacy-4.56771.47810.9607
Inactive0-7.768610.69720.758810.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.08229.0278.56537.5724.21540.90080.24680.02675.66910.0433-7.0E-4-2.28440.3557-1.0822QC'd by SIGMAInactive0
Activator17.351737.620340Partial curve; high efficacy-4.76073.06540.989337.3935-0.22682.10 0 0 0 0 0 0 0 0 0 0 0 0 0 124.0027-1.13920.1686-0.1252-1.4390.2351-0.49480.65421.28420.05961.310721.815534.209324.0027QC'd by SIGMAActivator4.890445.728181Complete curve; high efficacy-5.31070.70.9547
Inactive00040.5220.023-1.1865-1.4762-0.05160.6407-0.0477-0.5943-1.0553-3.4872-1.7526-1.5011-0.45170.522QC'd by SIGMAInactive0-5.56914.95490.4552
Inactive0-4.27133.29750.65377-0.991840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.71270.1065-2.9589-3.3265-0.1367-0.53720.1194-0.7792-2.1668-3.2131-0.01280.58790.97235.7127QC'd by SigmaAldrichInactive0-4.12134.95490.6439
Inactive0004-4.945-2.5611-5.5604-5.5744-3.7841-2.51970.8205-4.2283-4.7634-6.5963-6.2633-3.1896-5.8718-4.945QC'd by SIGMAInactive0
Inactive0-4.16290.60.42327-1.160340 0 0 0 0 0 0 0 0 0 0 0 0 0 04.3597-0.362-3.0077-3.05030.2438-1.01930.3335-0.4699-1.28130.401-0.46414.3554-0.91184.3597QC'd by SIGMAInactive0-5.51292.33320.8433
Inactive0004-0.70380.0361-3.7089-1.7915-1.25830.16870.69770.1566-2.4696-3.4971-1.51-1.5395-3.4697-0.7038QC'd by SIGMAInactive0
Inactive0004-1.2777-1.6943-2.5955-3.5033-1.64891.17161.2363-2.1104-2.9787-3.3438-1.1157-1.1422-1.1735-1.2777QC'd by SIGMAInactive0
Inactive0004-0.56630.288-2.3707-2.7283-0.63382.07513.38390.0802-2.4707-3.83610.0879-0.2454-2.8389-0.5663QC'd by SIGMAInactive0-4.85851.88510.9504
Inactive0004-1.1005-0.9792-1.7954-2.6037-0.12-0.26040.3413-0.8959-1.9784-3.2297-1.6711-0.0062-3.6975-1.1005QC'd by SIGMAInactive0
Inactive0004-1.2459-4.784-9.0537-2.2125-3.0446-0.91621.9784-0.3992-6.2878-10.5833-9.5972-2.1042-10.227-1.2459QC'd by SIGMAInactive0
Inactive0004-1.0084-1.7104-1.9369-2.0369-1.6802-0.573-0.47480.085-2.3375-4.3727-2.4796-2.5942-2.7424-1.0084QC'd by SIGMAInactive0
Inactive0004-0.9643-2.3604-0.8724-2.1936-0.583-0.2670.1582-0.3325-2.7466-3.9462-1.2392-0.1393-2.9256-0.9643QC'd by SigmaAldrichInactive0
Inactive0004-6.2696-3.3484-4.8795-5.0177-4.9214-3.95680.8092-3.9748-5.0443-6.7588-5.093-3.1627-6.7773-6.2696QC'd by ChemServiceInactive0
Inactive0004-3.7787-1.21870.3496-1.1618-0.178-0.02990.1049-1.7277-1.4204-3.3075-1.8639-0.2976-4.4158-3.7787QC'd by SIGMAInactive0
Inactive0004-5.5543-3.7243-4.3348-6.0183-4.46860.85250.2555-1.1073-5.5639-6.2665-7.6529-4.829-7.4675-5.5543QC'd by SIGMAInactive0
Activator21.579778.216381Complete curve; high efficacy-4.6662.47290.975179.1210.90471.10 0 0 0 0 0 0 0 0 0 0 0 0 0 079.9059-0.6357-0.03330.1670.65420.84030.39860.65146.9793-1.6191.148938.519460.089479.9059QC'd by FisherActivator24.212873.718240Partial curve; high efficacy-4.6161.10.9797
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR224
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195 (final concentration = 0.75 uM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.7001-2.07971.16113.0882-0.077102.1698.77392.9614-2.21710.116619.58354.13960.7001QC'd by ACCInactive0-4.52511.10.5248
Inactive00046.4354-1.02440.0097-0.0933-1.85581.1884-0.92732.35142.15013.76020.1771-1.03550.10946.4354QC'd by ACCInactive0
Inconclusive14.960164.783610Partial curve; high efficacy-4.82511.55790.966665.88741.10382.10 0 0 0 0 0 0 0 0 0 0 0 0 0 064.59921.6564-1.48951.3624-0.33672.53023.07761.2257-1.3673-1.46236.837225.336734.910764.5992QC'd by ACCInconclusive29.849380.826810Partial curve; high efficacy-4.52512.25260.8962
Inactive00047.00811.6498-1.43860.50060.40820.79470.89650.34840.35820.30331.35526.99592.91727.0081QC'd by ACCInactive0
Inactive00043.05635.54866.72620.53512.71380.70682.23040.2851-1.53215.16263.86991.54890.8433.0563QC'd by RTIInactive0
Inactive00040.74666.36313.94348.84614.56211.575.48974.19182.16295.86320.50451.34453.99310.7466QC'd by RTIInactive0
Inactive00040.67381.12332.28591.01811.5966-0.43621.77940.2945-1.37111.71640.89490.65662.50770.6738QC'd by RTIInactive0
Inactive00041.00343.59883.74021.61832.4828-24.1996-11.8417-15.26063.54570.8131-0.0321-11.9734-1.31061.0034QC'd by RTIInactive0
Inactive0-4.18464.95490.9125-10.752.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.31021.06850.91324.13362.67391.81972.26761.87431.57794.70882.78081.3363-11.4583-9.3102QC'd by RTIInactive0-3.83464.50450.8486
Inactive0-4.15534.95490.6213-8.5472540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7063.03746.28947.39888.83679.30074.16635.48521.16012.64973.10975.62653.3473-6.706QC'd by RTIInactive0-4.50531.13410.921
Inactive0-4.07872.90230.7611-27.65215.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.71016.68477.71693.3955.081315.63232.80533.07480.28617.9345.15692.3389-1.44-19.7101QC'd by RTICytotoxic74.351457.123720Single point of activity-4.12872.90230.9124
Cytotoxic57.09755.000921Partial curve; partial efficacy-4.24343.57220.9446-54.11980.881-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.68171.44960.64610.87374.0413-0.6397-8.70514.50811.25313.61011.83811.5671-14.0711-46.6817QC'd by RTICytotoxic57.09772.527141Partial curve; partial efficacy-4.24342.35310.9803
Cytotoxic69.1718108.736442Partial curve; high efficacy-4.16012.63840.9717-107.06951.6669-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.11334.12134.26247.21762.32561.1447-8.56171.58873.20240.90921.8827-6.6983-25.0645-81.1133QC'd by RTICytotoxic54.9451118.001241Partial curve; high efficacy-4.26012.12110.9982
Inactive00041.23831.33150.88153.39274.07264.82921.16914.05412.98531.32630.32392.28032.47551.2383QC'd by RTIInactive0
Cytotoxic62.612238.428920Partial curve; partial efficacy; poor fit-4.20332.53340.9423-35.92892.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.44074.56793.2733.0004-0.82787.03151.32971.03340.94391.5864-0.53831.1816-10.0481-27.4407QC'd by RTICytotoxic55.803256.613421Partial curve; partial efficacy-4.25332.53340.9455
Cytotoxic34.636240.085420Partial curve; partial efficacy-4.46052.78680.9485-35.58544.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-37.55547.86573.08136.25493.50321.57814.64299.84995.08361.63343.0637-4.2032-21.4975-37.5554QC'd by RTICytotoxic48.92563.310741Partial curve; partial efficacy-4.31052.40640.966
Inactive0-4.95263.51170.4728-12.1793140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.88662.10451.60872.2705-1.9686-0.7779-1.63741.02741.49992.1762.5-23.0661-2.7817-0.8866QC'd by RTIInactive0-4.15262.63840.6052
Inactive0004-2.84033.5493.05938.34540.08545.4167-0.89290.03223.37180.29422.8684-1.08252.444-2.8403QC'd by RTIInactive0-4.09594.95490.8672
Inactive00040.57120.96791.09642.61560.08615.51343.14970.57852.83021.933.1832-1.67453.16860.5712QC'd by RTIInactive0
Inactive0-4.51414.95490.6339-9.2283240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.63681.3480.78612.61030.0177-0.69933.3843-0.57490.00933.38765.62053.6707-9.3569-0.6368QC'd by RTICytotoxic68.537737.040120Partial curve; partial efficacy; poor fit-4.16412.90230.9194
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR404
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO (final concentration = 50 nM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-1.2885-8.2133-8.16350-7.1502-6.0582-1.0685-6.9497-7.74221.4318-0.484-9.89-5.9739-1.2885QC'd by LightBiologicalsInactive0
Inactive0-4.21374.50450.3794-2.0019-11.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.2267-13.6359-11.5589-12.427-11.9862-12.3014-2.0849-11.776-12.2205-11.2807-10.5655-12.6043-10.0799-3.2267QC'd by SIGMAInactive0
Inactive0004-18.8355-16.5392-15.7843-14.6365-14.6435-14.8247-15.1826-17.2997-17.0567-15.571-15.4498-16.8771-18.7769-18.8355QC'd by SIGMAInactive0
Cytotoxic61.130668.499141Partial curve; partial efficacy-4.21373.57220.9855-82.6763-14.1772-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.8305-13.3313-15.7246-16.9851-15.1291-16.6431-12.0943-15.0603-13.2228-10.6311-12.392-15.5076-28.0786-69.8305QC'd by SIGMACytotoxic61.130688.918141Partial curve; high efficacy-4.21372.47290.9648
Inactive0004-9.4937-8.4802-2.4154-6.8019-7.6968-8.7013-4.9931-5.9136-8.161-5.4834-5.5854-7.8666-8.6242-9.4937QC'd by LightBiologicalsInactive0-8.06374.95490.5744
Inactive0-4.21373.29750.784-19.65540.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.54620.30110.54811.68972.3515-1.76286.6762-2.18030.3036-2.6294-0.6711-0.2348-3.468-15.5462QC'd by SIGMAInactive0-4.21370.40.6227
Inactive0004-0.8117-4.0669-9.8967-11.0574-6.4365-5.9282-6.3535-7.6972-5.2867-9.8338-1.3993-0.8947-7.6295-0.8117QC'd by SIGMAInactive0
Cytotoxic61.503855.678321Partial curve; partial efficacy-4.21113.990.9569-57.7149-2.0366-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.64770.26981.6175-2.9758-3.96481.7183-4.47090.3089-5.9715-1.9196-1.5152-1.5012-11.187-48.6477QC'd by ChemServiceInactive0-4.21114.95490.8972
Inactive0-4.11374.95490.6896-23.3009040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.75070.5104-1.55631.8378-3.19332.5092-0.693-8.08051.92620.04853.9244-2.18611.6782-17.7507QC'd by SIGMAInactive0-4.21374.0950.6638
Cytotoxic60.5715107.680742Partial curve; high efficacy-4.21771.86170.9797-127.4822-19.8016-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.5775-19.6657-16.6526-20.809-21.6607-19.7704-14.2217-18.8965-22.5975-21.7271-20.6249-34.5795-53.8367-96.5775QC'd by EPACytotoxic42.8813102.238741Partial curve; high efficacy-4.36771.96730.9874
Cytotoxic34.201550.561640Partial curve; partial efficacy-4.4661.46410.9284-54.0991-3.5375-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.0918-2.7848-1.0730.0864-3.1155-8.38860.2833-5.2666-5.937-8.2702-10.3681-18.193-25.3466-50.0918QC'd by CrescentCytotoxic30.482144.89120Partial curve; partial efficacy-4.5161.47810.9399
Inactive0-3.96370.80.6909-31.6-3.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23-4.3769-2.78840.141-3.552-4.8242-6.7976-4.9877-2.8309-6.1986-3.8792-6.6066-8.0591-23QC'd by Sigma DiscoveryCPRCytotoxic61.130637.500120Single point of activity-4.21373.62720.9475
Inactive00042.7896-2.2890.3967-3.4023-0.5931-3.73261.98680.266-0.04370.42130.10770.45910.0122.7896QC'd by SIGMAInactive0
Inactive00040.26690.57262.32333.2007-0.42921.18692.47032.29592.39542.45931.99820.27692.75730.2669QC'd by SIGMAInactive0
Inactive00040.15290.81242.78170.7373.17970.4171.1829-3.29880.4225-0.650.0220.90230.99470.1529QC'd by SIGMAInactive0
Inactive0-4.11374.95490.7475-10.5412240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11761.66523.16792.25360.69250.89822.26921.6541.01862.7189-0.12983.29222.2598-7.1176QC'd by SIGMAInactive0-4.56374.50450.3801
Inactive0004-3.2742-0.57391.18390.6992-0.1356-0.9956-3.9472-0.31020.02640.46931.55660.2082-3.8232-3.2742QC'd by SIGMAInactive0
Inactive0004-0.7927-6.5931-0.004-0.87430.5458-3.7497-2.0427-2.5866-3.6954-3.9867-18.7143-2.0222.5912-0.7927QC'd by SIGMAInactive0
Inactive0004-13.9982-8.8449-6.7122-3.2554-8.551-4.4661-2.4558-5.8647-10.1231-5.4289-3.8809-5.1227-8.4815-13.9982QC'd by SIGMAInactive0
Inactive0004-0.2549-3.2147-2.0568-1.3426-0.21941.32071.5504-1.1495-1.6104-0.5283-1.0103-2.0348-1.3745-0.2549QC'd by LightBiologicalsInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC875
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.3468-0.10070.0358-0.33470.23222.509-4.5860.2540.48071.16460.75384.1574-4.8525-0.3468QC'd by SIGMAInactive0
Inactive0004-3.3197-5.6995-7.8071-6.0662-4.9082-8.0484-7.708-4.8984-5.8365-2.5967-1.1821-5.7986-3.0963-3.3197QC'd by SigmaAldrichInactive0
Inactive00041.84520.97091.1435-0.24060.0731-0.12051.2062-0.18330.0921.20720.47061.31020.49521.8452QC'd by SIGMAInactive0-4.01730.70.5777
Inhibitor34.131725.96160Partial curve; partial efficacy-4.46682.33320.9617-25.96160-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.9681.69630.1516-1.09160.4925-0.73560.52772.66582.0E-4-2.8872-3.0257-4.5147-15.6179-24.968QC'd by SIGMAInhibitor48.212321.71050Partial curve; partial efficacy-4.31681.82650.8711
Inactive00041.39531.94521.30180.9104-0.31670.42261.07071.9713-0.37872.93970.83462.12710.21931.3953QC'd by SigmaAldrichInactive0
Inactive0-4.06334.95490.4301-7.0921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.24341.0247-0.6334-0.0593-0.5529-0.870.3563-3.05990.0772-2.04451.2375-0.9179-0.0839-4.2434QC'd by SIGMAInactive0-4.31333.51170.5308
Inactive0-5.75854.95490.3744-2.0452140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.39762.44991.9442.7333-0.72910.18521.02430.39980.1524-5.0377-4.45790.10940.3382-0.3976QC'd by SigmaAldrichInactive0
Inactive00044.02841.30910.502-2.96730.6114-3.0343-5.43691.67780.79992.43120.8290.0491.04384.0284QC'd by Alfa AesarInactive0
Inactive0-5.26464.95490.4346-2.0801140 0 0 0 0 0 0 0 0 0 0 0 0 0 11.98340.29922.4906-0.22330.3752.7141.88570.4384-0.23811.8609-3.01220.5146-3.40011.9834QC'd by SIGMAInactive0
Inactive00042.63350.03471.26840.123-0.3218-0.7076-0.30731.1541.4491.46540.89010.0407-0.34962.6335QC'd by SIGMAInactive0
Inactive0-4.09724.95490.45685-0.300340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4899-1.55050.48970.6246-0.8749-0.70910.3983-0.38271.38450.1489-2.3336-0.5514-0.29293.4899QC'd by SigmaAldrichInactive0
Activator42.573923.761320Partial curve; partial efficacy-4.37091.46410.9148240.23872.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.55410.00531.42-0.16480.3750.50141.6438-0.125-0.76833.78914.61832.97299.933520.5541QC'd by SIGMAActivator60.13733020Partial curve; partial efficacy-4.22092.53340.9705
Inactive00042.55290.4063-0.01020.18952.3191-1.84951.7387-1.9418-1.54353.99270.02911.34360.7672.5529QC'd by SIGMAInactive0-8.36331.28760.3456
Inactive00041.41240.5842.30430.55631.00343.2421-0.03291.7832-2.03062.37860.03731.3846-0.48531.4124QC'd by ChemServiceInactive0
Inactive00043.2372-0.06260.30520.0902-0.17460.25520.3996-0.2881.25733.132-0.27620.86140.24633.2372QC'd by SIGMAInactive0
Inactive00042.54410.50790.20260.3539-0.13770.985-0.3504-1.23841.32581.2338-2.15810.15631.45512.5441QC'd by SIGMAInactive0
Inactive0-4.17223.67720.6648-5.8375140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.03120.75431.06750.67620.09292.30830.48760.50432.7882-0.24950.6636-0.05580.1164-4.0312QC'd by City ChemicalInactive0
Inhibitor17.334135.94590Complete curve; high efficacy-4.76113.1320.981-35.94590-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.7947-1.1822-0.3985-2.19492.5399-2.8881-1.15330.37421.44382.4728-1.8207-20.2287-32.2128-36.7947QC'd by InterchemInhibitor15.44939.10510Complete curve; high efficacy-4.81112.33320.9633
Inactive0-4.17994.0950.4925-4.84510.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.62090.76960.04541.12750.09010.13020.2945-0.00821.2284-0.19962.4956-2.29050.011-3.6209QC'd by SIGMAInhibitor46.785537.00050Partial curve; partial efficacy-4.32991.69240.9362
Inactive0004-3.6855-2.20722.44460.09531.2718-2.0196-1.5529-1.1351-0.9412-2.5691-0.9983-2.4138-2.9275-3.6855QC'd by SIGMAActivator5.431631.161281Complete curve; high efficacy-5.26511.34430.9707
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Muscarinic acetylcholine receptor M3
External ID: CHEMBL747819
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2003
Volume: 46
Issue: 11
First Page: 2216
Last Page: 2226
DOI: 10.1021/jm020572p

Target ChEMBL ID: CHEMBL245
ChEMBL Target Name: Muscarinic acetylcholine receptor M3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
7.5Ki=7500nM
100Ki>100000nM